Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin | Zendy

Arpasiri Srisrattakarn | Zendy; Chonthicha CHAİYAPOKE | Zendy; Sirikarn BOONCHAROEN | Zendy; Sujintana Wongthong | Zendy; Aroonwadee Chanawong | Zendy; Patcharaporn Tippayawat | Zendy; Ratree Tavichakorntrakool | Zendy; Aroonlug Lulitad | Zendy

Open Access

Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin

Author(s) -

Arpasiri Srisrattakarn,

Chonthicha CHAİYAPOKE,

Sirikarn BOONCHAROEN,

Sujintana Wongthong,

Aroonwadee Chanawong,

Patcharaporn Tippayawat,

Ratree Tavichakorntrakool,

Aroonlug Lulitad

Publication year - 2021

Publication title -

turkish journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.277

H-Index - 27

eISSN - 1303-6165

pISSN - 1300-0144

DOI - 10.3906/sag-1910-166

Subject(s) - meropenem , imipenem , vancomycin , cefotaxime , microbiology and biotechnology , medicine , staphylococcus aureus , antibiotics , biology , bacteria , antibiotic resistance , genetics

We investigated the synergistic effect between vancomycin and β-lactams against vancomycin-susceptible (VSSA) and nonsusceptible MRSA isolates [heterogeneous vancomycin-intermediate S. aureus (hVISA) and VISA].

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research